Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Analysis of Proteins, Protein Complexes, and Organellar Proteomes Using Sheathless Capillary Zone Electrophoresis - Native Mass Spectrometry.

Belov AM, Viner R, Santos MR, Horn DM, Bern M, Karger BL, Ivanov AR.

J Am Soc Mass Spectrom. 2017 Dec;28(12):2614-2634. doi: 10.1007/s13361-017-1781-1. Epub 2017 Sep 5.

PMID:
28875426
2.

Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.

Pisupati K, Benet A, Tian Y, Okbazghi S, Kang J, Ford M, Saveliev S, Sen KI, Carlson E, Tolbert TJ, Ruotolo BT, Schwendeman SP, Schwendeman A.

MAbs. 2017 Oct;9(7):1197-1209. doi: 10.1080/19420862.2017.1347741. Epub 2017 Aug 8.

PMID:
28787231
3.

Pharmacokinetics of Monoclonal Antibodies.

Ryman JT, Meibohm B.

CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29.

4.

Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.

Miao S, Fan L, Zhao L, Ding D, Liu X, Wang H, Tan WS.

Biomed Res Int. 2017;2017:4926168. doi: 10.1155/2017/4926168. Epub 2017 Mar 2.

5.

Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components

Torkashvand F, Vaziri B.

Iran Biomed J. 2017 May;21(3):131-141. Epub 2017 Apr 20. Review.

6.
7.

Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.

Wang X, McKay P, Yee LT, Dutina G, Hass PE, Nijem I, Allison D, Cowan KJ, Lin K, Quarmby V, Yang J.

MAbs. 2017 Feb/Mar;9(2):319-332. doi: 10.1080/19420862.2016.1261774. Epub 2016 Dec 21.

PMID:
28001487
8.

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept.

Miranda-Hernández MP, López-Morales CA, Perdomo-Abúndez FC, Salazar-Flores RD, Ramírez-Ibanez ND, Pérez NO, Molina-Pérez A, Revilla-Beltri J, Flores-Ortiz LF, Medina-Rivero E.

J Immunol Res. 2016;2016:9697080. doi: 10.1155/2016/9697080. Epub 2016 Jun 12.

9.

Posttranslational Modifications and the Immunogenicity of Biotherapeutics.

Jefferis R.

J Immunol Res. 2016;2016:5358272. doi: 10.1155/2016/5358272. Epub 2016 Apr 14. Review.

10.

Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.

Datta-Mannan A, Croy JE, Schirtzinger L, Torgerson S, Breyer M, Wroblewski VJ.

MAbs. 2016 Jul;8(5):969-82. doi: 10.1080/19420862.2016.1178435.

11.

Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.

Zhao YY, Wang N, Liu WH, Tao WJ, Liu LL, Shen ZD.

PLoS One. 2016 Mar 17;11(3):e0151874. doi: 10.1371/journal.pone.0151874. eCollection 2016.

12.

Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.

Miranda-Hernández MP, López-Morales CA, Piña-Lara N, Perdomo-Abúndez FC, Pérez NO, Revilla-Beltri J, Molina-Pérez A, Estrada-Marín L, Flores-Ortiz LF, Ruiz-Argüelles A, Medina-Rivero E.

Biomed Res Int. 2015;2015:874916. doi: 10.1155/2015/874916. Epub 2015 Nov 19.

13.

Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.

Tibbitts J, Canter D, Graff R, Smith A, Khawli LA.

MAbs. 2016;8(2):229-45. doi: 10.1080/19420862.2015.1115937. Epub 2015 Dec 4. Review.

14.

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.

Datta-Mannan A, Lu J, Witcher DR, Leung D, Tang Y, Wroblewski VJ.

MAbs. 2015;7(6):1084-93. doi: 10.1080/19420862.2015.1075109. Epub 2015 Sep 4.

15.

Rapid quantitative analysis of monoclonal antibody heavy and light chain charge heterogeneity.

Vanam RP, Schneider MA, Marlow MS.

MAbs. 2015;7(6):1118-27. doi: 10.1080/19420862.2015.1085145. Epub 2015 Aug 25.

16.

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab).

Tebbey PW, Varga A, Naill M, Clewell J, Venema J.

MAbs. 2015;7(5):805-11. doi: 10.1080/19420862.2015.1073429.

17.

Physicochemical and biological characterization of a biosimilar trastuzumab.

López-Morales CA, Miranda-Hernández MP, Juárez-Bayardo LC, Ramírez-Ibáñez ND, Romero-Díaz AJ, Piña-Lara N, Campos-García VR, Pérez NO, Flores-Ortiz LF, Medina-Rivero E.

Biomed Res Int. 2015;2015:427235. doi: 10.1155/2015/427235. Epub 2015 May 17.

18.

A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.

Souders CA, Nelson SC, Wang Y, Crowley AR, Klempner MS, Thomas W Jr.

MAbs. 2015;7(5):912-21. doi: 10.1080/19420862.2015.1054585.

19.

Assessment of physicochemical properties of rituximab related to its immunomodulatory activity.

Miranda-Hernández MP, López-Morales CA, Ramírez-Ibáñez ND, Piña-Lara N, Pérez NO, Molina-Pérez A, Revilla-Beltri J, Flores-Ortiz LF, Medina-Rivero E.

J Immunol Res. 2015;2015:910763. doi: 10.1155/2015/910763. Epub 2015 Apr 20.

20.

Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.

Majumdar R, Esfandiary R, Bishop SM, Samra HS, Middaugh CR, Volkin DB, Weis DD.

MAbs. 2015;7(1):84-95. doi: 10.4161/19420862.2014.985494.

Supplemental Content

Support Center